ProCE Banner Activity

Assessing Adverse Events in Patients Receiving Chemoimmunotherapy Regimens for Non-Small-Cell Lung Cancer

Tool

Use this Interactive Decision Support Tool to aid in the evaluation of adverse events in patients receiving combination chemoimmunotherapy regimens for non-small-cell lung cancer.

Released: October 19, 2023

Share

Faculty

Marianne Davies

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager, Care Signature
Oncology Service Line
Yale New Haven Health
Oncology Nurse Practitioner- Senior APP II
Smilow Cancer Hospital, Yale-New Haven
Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

Matthew Gubens

Matthew Gubens, MD, MS, FASCO

Professor of Medicine
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Faculty Disclosure

Primary Author

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager, Care Signature
Oncology Service Line
Yale New Haven Health
Oncology Nurse Practitioner- Senior APP II
Smilow Cancer Hospital, Yale-New Haven
Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

Marianne Davies, DNP, ACNP, FAAN, has no relevant financial relationships to disclose.

Matthew Gubens, MD, MS, FASCO

Professor of Medicine
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS: consultant/advisor/speaker: AnHeart, AstraZeneca, Atreca, Cardinal Health, Genentech/Roche, Genzyme, Gilead, Guardant, Invitae, iTeos, Merus, Sanofi, Summit, Surface; researcher (paid to institution): Amgen, Celgene, Johnson & Johnson, Merck, Novartis, OncoMed, Trizell.